Can a diabetes drug protect dialysis Patients' hearts?
NCT ID NCT07527390
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests how the diabetes drug canagliflozin (Invokana) spreads through the body in 10 dialysis patients with severe kidney disease. Using PET scans, researchers want to see if the drug reaches tissues like the heart and blood vessels, not just the kidneys. The goal is to understand if these drugs could offer protection beyond the kidneys in people on dialysis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Canagliflozin (Invokana) tablet
- What this could lead to
- If successful, this could show that SGLT2 inhibitors like canagliflozin reach and protect the heart and blood vessels even in dialysis patients, possibly leading to new treatments for this group.
- What could go wrong
- This is a very small, early-phase study with only 10 participants, focused on imaging rather than health outcomes. It may not prove any clinical benefit or safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (STAGES 4 AND 5) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Medical Center Groningen
Groningen, Provincie Groningen, 9713 GZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors
- A simple stretch during dialysis might soothe restless legs
- Can a single dose of zoledronic acid safely treat bone loss in dialysis patients?
- A softer path for kidney disease: could palliative care ease the burden?